{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+solution&page=29",
    "query": {
      "intervention": "placebo solution",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 3139,
    "total_pages": 314,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+solution&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+solution&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T16:06:03.097Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04642404",
      "title": "CBD for Dental Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Odontalgia",
        "Toothache"
      ],
      "interventions": [
        {
          "name": "Epidiolex 100 mg/mL Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 64,
      "start_date": "2021-03-01",
      "completion_date": "2023-03-13",
      "has_results": true,
      "last_update_posted_date": "2024-05-09",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04642404"
    },
    {
      "nct_id": "NCT03580356",
      "title": "A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "Ligelizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Omalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1078,
      "start_date": "2018-10-20",
      "completion_date": "2022-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03580356"
    },
    {
      "nct_id": "NCT00973856",
      "title": "Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Papillomavirus Infections",
        "Warts",
        "Condylomata Acuminata",
        "Epidermodysplasia Verruciformis"
      ],
      "interventions": [
        {
          "name": "PURELL VF481",
          "type": "OTHER"
        },
        {
          "name": "Placebo Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Cleveland Clinic Akron General",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 5,
      "start_date": "2009-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 1,
      "location_summary": "Akron, Ohio",
      "locations": [
        {
          "city": "Akron",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00973856"
    },
    {
      "nct_id": "NCT03397966",
      "title": "Metabolic Effects of Natriuretic Peptide Hormones",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity",
        "Cardiovascular Physiological Phenomena",
        "Metabolism"
      ],
      "interventions": [
        {
          "name": "recombinant human BNP(1-32)",
          "type": "DRUG"
        },
        {
          "name": "placebo (control, normal saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-07-01",
      "completion_date": "2019-05-01",
      "has_results": true,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03397966"
    },
    {
      "nct_id": "NCT04364737",
      "title": "CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Coronavirus",
        "Coronavirus Infection"
      ],
      "interventions": [
        {
          "name": "Convalescent Plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 941,
      "start_date": "2020-04-17",
      "completion_date": "2022-12-12",
      "has_results": true,
      "last_update_posted_date": "2023-01-26",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 9,
      "location_summary": "New Haven, Connecticut • Miami, Florida • New York, New York + 5 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Edinburg",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04364737"
    },
    {
      "nct_id": "NCT03298867",
      "title": "Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease",
        "Graves' Orbitopathy"
      ],
      "interventions": [
        {
          "name": "Teprotumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 83,
      "start_date": "2017-10-04",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 9,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03298867"
    },
    {
      "nct_id": "NCT04113109",
      "title": "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "LCZ 696",
          "type": "DRUG"
        },
        {
          "name": "Icatibant",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Para-aminohippurate",
          "type": "DRUG"
        },
        {
          "name": "Iohexol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2019-11-01",
      "completion_date": "2025-07-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04113109"
    },
    {
      "nct_id": "NCT07122193",
      "title": "A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromuscular Agents",
        "Peripheral Nervous System Agents",
        "Physiological Effects of Drugs",
        "Acetylcholine Release Inhibitors",
        "Membrane Transport Modulators",
        "Molecular Mechanisms of Pharmacological Action",
        "Cholinergic Agents",
        "Neurotransmitter Agents",
        "incobotulinumtoxinA",
        "Botulinum Toxins, Type A"
      ],
      "interventions": [
        {
          "name": "NT 201",
          "type": "DRUG"
        },
        {
          "name": "NT 201 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz North America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-08-27",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 27,
      "location_summary": "Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07122193"
    },
    {
      "nct_id": "NCT00125502",
      "title": "Recombinant CMV gB Vaccine in Postpartum Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [
        {
          "name": "CMV gB vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59 adjuvant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Robert Pass, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 40 Years · Female only"
      },
      "enrollment_count": 464,
      "start_date": "1999-08",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2011-09-20",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125502"
    },
    {
      "nct_id": "NCT04614467",
      "title": "A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Microvascular Dysfunction",
        "Coronary Microvascular Disease",
        "Microvascular Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "CLBS16",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lisata Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2020-10-29",
      "completion_date": "2022-09-28",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-29T16:06:03.097Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Hollywood, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04614467"
    }
  ]
}